Drug Profile


Alternative Names: E 64 D; EST; Estate; Loxistatin; Rexostatine

Latest Information Update: 03 Apr 1996

Price : $50

At a glance

  • Originator Taisho Pharmaceutical
  • Developer Sumitomo Pharmaceuticals; Taisho Pharmaceutical
  • Class Antineoplastics; Eye disorder therapies
  • Mechanism of Action Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Muscular dystrophies

Most Recent Events

  • 03 Apr 1996 Discontinued-Clinical for Muscular dystrophy in Japan (Unknown route)
  • 28 Mar 1996 Investigation in Muscular dystrophy in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top